ClinicalTrials.gg
CompletedNCT04477096Updated Oct 1, 2020

Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine

A Phase 1 interventional study of HS-10234 and Emtricitabine in Healthy Subjects, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-01.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study is being conducted to evaluate drug interaction between HS-10234 and Emtricitabine after multiple dose in healthy subjects.

Read the detailed description

The study includes two parts. Part 1 is to evaluate the impact of Emtricitabine on HS-10234. Part 2 is to evaluate the impact of HS-10234 on Emtricitabine.

02

Conditions studied

  • Healthy Subjects

Keywords

  • HIV
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign an before any activities related to this trial and understand the procedures and methods of this trial;
  2. Aged between 18 and 55 years old (including cutoff value), both male and female;
  3. Male body weight ≥50.0kg, female body weight ≥45.0kg, (BMI) is 19\~26 kg/m2 (including both ends);
  4. Those who signed the informed consent form and had no birth plan within 3 months after the last dose and agreed to take effective measures.

Exclusion criteria

Exclusion Criteria:

  1. People who have been or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other diseases that can interfere with the test results, Or have a stomach problem or have a history of stomach problems;
  2. People who have drugs (penicillin or cephalosporin drugs), food, or have a history of allergy to test drugs or similar drugs;
  3. If the subject have a history of surgery within the 4 weeks prior to the trial or plan to undergo surgery during the study period or have surgery that affected the absorption, distribution, metabolism, and excretion of drugs;
  4. Those who took any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before taking the study drug, or those who were within 5 half-lives of the drug at the time of screening; those who plan to take non-study drugs or health products during the trial;
  5. Those who participated in any drug clinical trial and used any trial drug within 3 months before administration (subject to the );
  6. Participate in blood donation within 3 months before administration and the amount of blood donation >200 mL, or have received blood transfusion;
  7. Unable or unwilling to follow the lifestyle guidelines required in the plan;
  8. Smokers or those who smoked more than 5 cigarettes per day in the 3 months before the trial;
  9. Alcoholics or frequent drinkers within 6 months before the test, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) or before administration Alcohol screening positive;
  10. People who have a history of drug abuse, drug dependence, or a positive drug screen before administration;
  11. Screening/baseline visit to and/or aspartate aminotransferase and/or alkaline phosphatase and/or total exceeds 1.2 times the ;
  12. Abnormal vital signs (systolic blood pressure \<90 mmHg or >140 mmHg, diastolic blood pressure \<50 mmHg or >90 mmHg; pulse \<50 bpm or >100 bpm) or physical examination, , laboratory examination, imaging examination, etc. Abnormality has clinical significance (subject to the judgment of the clinical research doctor);
  13. The is prolonged during screening (calculated using Bazett's method, male>450 msec, female>460 msec);
  14. surface antigen, antibody, syphilis serotonin, antibody test positive;
  15. Women during pregnancy or lactation;
  16. Subjects may not be able to complete the study for other reasons or the investigator believes that they should not be included.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Other
    single arm for each part: two arms

    PART1:In the first period, HS-10234 will be administered at 25 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days. PART2:In the first period, Emtricitabine will be administered at 200 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days.

    Drug: HS-10234 · Drug: Emtricitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics parameters of HS-10234 and it's metabolite tenofovir, Emtricitabine

    Cmax

    Time frame: 0 - 24 hour on 7th day

  2. Pharmacokinetics parameters of HS-10234 and it's metabolite tenofovir, Emtricitabine

    AUC0-tau

    Time frame: 0 - 24 hour on 7th day

Secondary outcomes

  1. Concentration of HS-10234's metabolite tenofovir-diphosphate in peripheral blood mononuclear cells.

    Concentration

    Time frame: 0 - 24 hour on 7th day

  2. Incidence of AEs,

    laboratory abnormalities (based on hematology, biochemistry, and urinalysis tests)

    Time frame: 0 - 23 day

  3. Incidence of AEs,

    body temperature

    Time frame: 0 - 23 day

  4. Incidence of AEs,

    respiratory rate

    Time frame: 0 - 23 day

  5. Incidence of AEs,

    blood pressure

    Time frame: 0 - 23 day

  6. Incidence of AEs,

    pulse rate

    Time frame: 0 - 23 day

  7. Incidence of AEs,

    Resting 12-lead ECG parameters(ECG QT Interval)

    Time frame: 0 - 23 day

07

Study locations

1 site
  • Xiangya Hospital, Central South University
    Changsha, Hunan 410013, China
08

References and documents

Publications

  • Luo Y, Chen W, Yang G, Zou C, Huang J, Kuang Y, Shen K, Zhang B, Yang S, Xiang H, Li Z, Pei Q. Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial. Infect Dis Ther. 2022 Feb;11(1):175-186. doi: 10.1007/s40121-021-00555-y. Epub 2021 Oct 30. PubMed 34727366 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Sep 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2020
First posted
Jul 20, 2020
StartActual
Aug 3, 2020
Primary completionActual
Sep 24, 2020
CompletionActual
Sep 24, 2020
Last update
Oct 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04477096
Responsible party
Sponsor
First posted
Jul 20, 2020
Start date
Aug 3, 2020
Primary completion
Sep 24, 2020
Completion
Sep 24, 2020
Last update
Oct 1, 2020

Study contacts

Guoping Yang
principal investigator · Xiangya Hospital of Central South University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HS-10234 · Emtricitabine

Start the discussion